Dried blood spots for HIV-1 drug resistance and viral load testing: A review of current knowledge and WHO efforts for global HIV drug resistance surveillance

AIDS Reviews

Volumn 12, Issue 4, 2010, Pages 195-208

  Bertagnolio, Silvia ^a   Parkin, Neil T ^b   Jordan, Michael ^a,c   Brooks, James ^d   García Lerma, J Gerardo ^e  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b DATA FIRST CONSULTING INC   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

DBS; Drug resistance; Filter paper; Genotyping; HIV 1; Surveillance; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; DNA; NUCLEIC ACID;

ACCREDITATION; BLOOD SAMPLING; CLINICAL ASSESSMENT; DISEASE SURVEILLANCE; DRIED BLOOD SPOT; DRIED PLASMA SPOT; DRIED SERUM SPOT; EXTRACTION; FILTER; FREEZE THAWING; GENE AMPLIFICATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; KNOWLEDGE; LABORATORY TEST; NONHUMAN; PLASMA; QUALITY CONTROL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; STORAGE; VIRUS LOAD; VIRUS RECOMBINATION; VIRUS RESISTANCE; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

ANTI-HIV AGENTS; BLOOD SPECIMEN COLLECTION; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; POLYMERASE CHAIN REACTION; POPULATION SURVEILLANCE; VIRAL LOAD; WORLD HEALTH ORGANIZATION;

EID: 79955705373     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. UNAIDS-WHO. AIDS epidemic update. Geneva: UNAIDS; 2002.
2. UNAIDS-WHO. Towards Universal Access: Scaling up priority HIV/AIDS interventions in the health sector. Progress Report, 2009. Geneva: UNAIDS; 2009.
3. Gilks C, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet. 2006;368:505-10. (Pubitemid 44142772)
4. Bennett D, Bertagnolio S, Sutherland D, Gilks C. The World Health Or ganization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther. 2008;13(Suppl 2):1-13. (Pubitemid 352019085)
5. Jordan M, Bennett D, Bertagnolio S, Gilks C, Sutherland D. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther. 2008;13(Suppl 2):15-23. (Pubitemid 352019086)
6. Bennett D, Myatt M, Bertagnolio S, Sutherland D, Gilks C. Recommenda tions for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther. 2008;13(Suppl 2):25-36. (Pubitemid 352019087)
7. Myatt M, Bennett D. A novel sequential sampling technique for the surveillance of transmitted HIV drug resistance by cross-sectional survey for use in low resource settings. Antivir Ther. 2008;13(Suppl 2):37-48. (Pubitemid 352019088)
8. Parkin N, Coakley E, Petropoulos C. Phenotypic Susceptibility Assays for Human Immunodeficiency Virus Type 1. In: LaFemina R, editor. Antiviral Research: Strategies in Antiviral Drug Discovery Washington DC: ASM Press. 2009;283-99.
9. Shafer R. Genotype testing for human immunodeficiency virus type 1 drug resistance Clin Microbiol Rev 2002;15:247-77.
10. Hamers R, Smit P, Stevens W, Schuurman R, Rinke de Wit T. Dried fluid spots for HIV type-1 viral load and resistance genotyping: a systematic review. Antivir Ther. 2009;14:619-29.
11. Uttayamakul S, Likanonsakul S, Sunthornkachit R, et al. Usage of dried blood spots for molecular diagnosis and monitoring HIV-1 infection. J Virol Methods. 2005;128:128-34. (Pubitemid 40980218)
12. Bertagnolio S, Soto-Ramirez L, Pilon R, et al. HIV-1 drug resistance surveil lance using dried whole blood spots. Antivir Ther. 2007;12:107-13. (Pubitemid 46340432)
13. Buckton A, Bissett S, Myers R, et al. Development and optimization of an internally controlled dried blood spot assay for surveillance of human immunodeficiency virus type-1 drug resistance. J Antimicrob Chemother. 2008;62:1191-8.
14. Dachraoui R, Depatureaux A, Chakroun M, et al. Monitoring of HIV-1 resistance in Tunisia (North Africa) with a dried plasma spot strategy. J Acquir Immune Defic Syndr 2008;47:522-5. (Pubitemid 351366953)
15. Garcia-Lerma J, McNulty A, Jennings C, Huang D, Heneine W, Bremer J. Rapid decline in the efficiency of HIV drug resistance genotyping from dried blood spots (DBS) and dried plasma spots (DPS) stored at 37 °C and high humidity. J Antimicrob Chemother. 2009;64:33-6.
16. Garrido C, Zahonero N, Fernandes D, et al. Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola. J Antimicrob Chemoth er. 2008;61:694-8. (Pubitemid 351321149)
17. Hallack R, Doherty L, Wethers J, Parker M. Evaluation of dried blood spot specimens for HIV-1 drug-resistance testing using the Trugene HIV-1 genotyping assay. J Clin Virol. 2008;41:283-7.
18. Masciotra S, Garrido C, Youngpairoj A, et al. High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients. AIDS. 2007;21:2503-11. (Pubitemid 350145182)
19. McNulty A, Jennings C, Bennett D, et al. Evaluation of dried blood spots for human immunodeficiency virus type 1 drug resistance testing. J Clin Microbiol. 2007;45:517-21.
20. Monleau M, Montavon C, Laurent C, et al. Evaluation of different RNA extraction methods and storage conditions of dried plasma or blood spots for human immunodeficiency virus type 1 RNA quantification and PCR amplification for drug resistance testing. J Clin Microbiol. 2009;47:1107-18.
21. Nelson J, Loftis A, Kamwendo D, et al. Nevirapine resistance in human immunodeficiency virus type 1-positive infants determined using dried blood spots stored for up to six years at room temperature. J Clin Microbiol. 2009;47:1209-11.
22. Plantier J, Dachraoui R, Lemee V, et al. HIV-1 resistance genotyping on dried serum spots. AIDS 2005;19:391-7. (Pubitemid 40446185)
23. Steegen K, Luchters S, Demecheleer E, et al. Feasibility of detecting human immunodeficiency virus type 1 drug resistance in DNA ex tracted from whole blood or dried blood spots. J Clin Microbiol. 2007;45:3342-51. (Pubitemid 47585660)
24. Youngpairoj A, Masciotra S, Garrido C, Zahonero N, de Mendoza C, Garcia-Lerma J. HIV-1 drug resistance genotyping from dried blood spots stored for 1 year at 4 °C. J Antimicrob Chemother. 2008;61:1217-20. (Pubitemid 351753584)
25. Ziemniak C, George-Agwu A, Moss W, Ray S, Persaud D. A sensitive genotyping assay for detection of drug resistance mutations in reverse transcriptase of HIV-1 subtypes B and C in samples stored as dried blood spots or frozen RNA extracts. J Virol Methods. 2006;136:238-47. (Pubitemid 44051599)
26. Mwaba P, Cassol S, Nunn A, et al. Whole blood versus plasma spots for measurement of HIV-1 viral load in HIV-infected African patients. Lancet. 2003;362:2067-8. (Pubitemid 38032761)
27. Solomon SS, Solomon S, Rodriguez I, et al. Dried blood spots (DBS): a valuable tool for HIV surveillance in developing/tropical countries. Int J STD AIDS. 2002;13:25-8. (Pubitemid 34032999)
28. Kane C, Ndiaye H, Diallo S, et al. Quantitation of HIV-1 RNA in dried blood spots by the real-time NucliSENS EasyQ HIV-1 assay in Senegal. J Virolog Method. 2008;148:291-5.
29. Hearps A, Ryan C, Morris L, Plate M, Greengrass V, Crowe S. Stability of dried blood spots for HIV-1 drug resistance analysis. Curr HIV Res. 2010;8:134-40.
30. Wallis C, Bell C, Horsfield P, Rinke de Wit T, Stevens W. Affordable resistance test for Africa (ARTA): DBS storage and extraction conditions for HIV subtype C. The 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa; 2009.
31. Somi G, Kibuka T, Diallo K, et al. Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania. Antivir Ther. 2008;13(Suppl 2):77-82.
32. Kamoto K, Aberle-Grasse J. Surveillance of transmitted HIV drug resistance with the World Health Organization threshold survey method in Lilongwe, Malawi. Antivir Ther. 2008;13(Suppl 2):83-7.
33. Lira R, Valdez-Salazar H, Vazquez-Rosales G, et al. Genotypic testing for HIV-1 drug resistance using dried blood samples. Arch Virol. 2010;155:1117-25.
34. Stevens W, Scott L, Crowe S. Quantifying HIV for monitoring antiretroviral therapy in resource-poor settings. J Infect Dis. 2010;201(Suppl 1):S16-26.
35. Mbida A, Sosso S, Flon P, et al. Measure of viral load by using the Abbott Real-Time HIV-1 assay on dried blood and plasma spot specimens collected in 2 rural dispensaries in Cameroon. J Acquir Immune Defic Syndr. 2009;52:9-16.
36. Andreotti M, Pirillo M, Guidotti G, et al. Correlation between HIV-1 viral load quantification in plasma, dried blood spots, and dried plasma spots using the Roche COBAS Taqman assay. J Clin Virol. 2010;47:4-7.
37. Garrido C, Zahonero N, Corral A, Arredondo M, Soriano V, de Mendoza C. Correlation between human immunodeficiency virus type 1 (HIV-1) RNA measurements obtained with dried blood spots and those obtained with plasma by use of Nuclisens EasyQ HIV-1 and Abbott RealTime HIV load tests. J Clin Microbiol. 2009;47:1031-6.
38. Reigadas S, Schrive M, Aurillac-Lavignolle V, Fleury H. Quantitation of HIV-1 RNA in dried blood and plasma spots. J Virolog Methods. 2009;161:177-80.
39. Lofgren S, Morrissey A, Chevallier C, et al. Evaluation of a dried blood spot HIV-1 RNA program for early infant diagnosis and viral load monitoring at rural and remote healthcare facilities. AIDS. 2009;23:2459-66.
40. Monleau M, Butel C, Delaporte E, Boillot F, Peeters M. Effect of storage conditions of dried plasma and blood spots on HIV-1 RNA quantification and PCR amplification for drug resistance genotyping. J Antimicrob Chemother. 2010;65:1562-6.
41. Waters L, Kambugu A, Tibenderana H, et al. Evaluation of filter paper transfer of whole-blood and plasma samples for quantifying HIV RNA in subjects on antiretroviral therapy in Uganda. J Acquir Immune Defic Syndr. 2007;46:590-3. (Pubitemid 350191052)
42. Johannessen A, Garrido C, Zahonero N, et al. Dried blood spots perform well in viral load monitoring of patients who receive antiretroviral treatment in rural Tanzania. Clin Infect Dis. 2009;49:976-81.
43. Wan H, Seth A, Rainen L, Fernandes H. Coamplification of HIV-1 proviral DNA and viral RNA in assays used for quantification of HIV-1 RNA. J Clin Microbiol. 2010;48:2186-90.
44. Leelawiwat W, Young N, Chaowanachan T, et al. Dried blood spots for the diagnosis and quantitation of HIV-1: stability studies and evaluation of sensitivity and specificity for the diagnosis of infant HIV-1 infection in Thailand. J Virolog Methods. 2009;155:109-17.
45. Mehta N, Trzmielina S, Nonyane B, et al. Low-cost HIV-1 diagnosis and quantification in dried blood spots by real time PCR. PLoS One. 2009;4:e5819.
46. Bruisten S, Reiss P, Loeliger A, et al. Cellular proviral HIV type 1 DNA load persists after long-term RT-inhibitor therapy in HIV type 1 infected persons. AIDS Res Hum Retrovir. 1998;14:1053-8. (Pubitemid 28371337)
47. Chun T, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997;387:183-8. (Pubitemid 27209433)
48. Escaich S, Ritter J, Rougier P, et al. Relevance of the quantitative detection of HIV proviral sequences in PBMC of infected individuals. AIDS Res Hum Retrovir. 1992;8:1833-7.
49. Bi X, Gatanaga H, Ida S, et al. Emergence of protease inhibitor resis tance-associated mutations in plasma HIV-1 precedes that in proviruses of peripheral blood mononuclear cells by more than a year. J Acquir Immune Defic Syndr. 2003;34:1-6. (Pubitemid 37100105)
50. Chew C, Potter S, Wang B, et al. Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART. J Clin Virol. 2005;33:206-16. (Pubitemid 40720440)
51. Koch N, Yahi N, Ariasi F, Fantini J, Tamalet C. Comparison of human im munodeficiency virus type 1 (HIV-1) protease mutations in HIV-1 genomes detected in plasma and in peripheral blood mononuclear cells from patients receiving combination drug therapy. J Clin Microbiol. 1999;37:1595-7. (Pubitemid 29187845)
52. Venturi G, Romano L, Carli T, et al. Divergent distribution of HIV-1 drug-resistant variants on and off antiretroviral therapy Antivir Ther. 2002;7:245-50.
53. Verhofstede C, Wanzeele F, Van Der Gucht B, De Cabooter N, Plum J. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. AIDS. 1999;13:2541-6. (Pubitemid 30038032)
54. Bennett D, Winters M, Shafer R, et al. Concordance of HIV drug resistance genotyping results for paired PBMC and plasma specimens from persons newly diagnosed with HIV. Antivir Ther. 2005;10:S176.
55. Zhang J, Kang D, Fu J, et al. Surveillance of transmitted HIV type 1 drug resistance in newly diagnosed hiv type 1-infected patients in Shandong Province, China. AIDS Res Hum Retrovir. 2010;26:99-103
56. Mousavi S, Hamkar R, Gouya M, et al. Surveillance of HIV drug resistance transmission in Iran: experience gained from a pilot study Arch Virol. 2010;155:329-34.
57. Bertagnolio S, Derdelinckx I, Parker M, et al. World Health Organization/ HIVResNet Drug Resistance Laboratory Strategy Antivir Ther. 2008; 13(Suppl 2):49-57. (Pubitemid 352019089)
58. Galli R, Sattha B, Wynhoven B, O'Shaughnessy M, Harrigan P. Sources and magnitude of intralaboratory variability in a sequence-based geno typic assay for human immunodeficiency virus type 1 drug resistance. J Clin Microbiol. 2003;41:2900-7. (Pubitemid 36842277)
59. Huang D, Bremer J, Brambilla D, et al. Model for assessment of profi ciency of human immunodeficiency virus type 1 sequencing-based ge notypic antiretroviral assays. J Clin Microbiol 2005;43:3963-70. (Pubitemid 41129687)
60. Korn K, Reil H, Walter H, Schmidt B. Quality control trial for human im munodeficiency virus type 1 drug resistance testing using clinical sam ples reveals problems with detecting minority species and interpretation of test results. J Clin Microbiol. 2003;41:3559-65. (Pubitemid 36994682)
61. Neuwald P, Funelas M, DelCarmen J, Raybold A, Jorgensen P. Results of the 2001 AcroMetrix HIV-1 resistance proficiency program. J Clin Virol. 2002;25(Suppl 3):S55-63.
62. Sayer D, Land S, Gizzarelli L, et al. Quality assessment program for genotypic antiretroviral testing improves detection of drug resistance mutations. J Clin Microbiol. 2003;41:227-36. (Pubitemid 36098581)
63. Schuurman R, Brambilla D, de Groot T, et al. Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. AIDS Res Hum Retrovir. 2002;18:243-8. (Pubitemid 34253141)
64. Parkin N, Fitzgibbon J, Bremer J, Bertagnolio S. HIV drug resistance genotyping external quality assurance (EQA) for laboratories in the World Health Organization (WHO) ResNet during 2007-2009. Antivir Ther. 2009;14(Suppl 1):A162.
65. Descamps D, Delaugerre C, Masquelier B, et al. Repeated HIV-1 resis tance genotyping external quality assessments improve virology labora tory performance. J Med Virol. 2006;78:153-60. (Pubitemid 43132558)
66. Johnson V, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med 2009;17:138-45.
67. Probst J, Brechtel S, Scheel B, et al. Characterization of the ribonuclease activity on the skin surface. Genet Vaccines Ther. 2006;4:4.
68. Keck J, Goedken E, Marqusee S. Activation/attenuation model for RNase H. A one-metal mechanism with second-metal inhibition. J Biol Chem. 1998;273:34128-33.